WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.

CEO

Mariusz Olejniczak

Employees

Country

Canada

ISIN

CA92941F2044

WKN

000A2PX9R

Listings

0 Comments

Share your thoughts

FAQs

What is WPD Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange WPD Pharmaceuticals stocks are traded under the ticker 8SV.STU.

What is WPD Pharmaceuticals revenue for the last year?▼

WPD Pharmaceuticals revenue for the last year amounts to 0 EUR.

What is WPD Pharmaceuticals net income for the last year?▼

8SV.STU net income for the last year is -56,909.56 EUR.

How many employees does WPD Pharmaceuticals have?▼

As of November 2, 2026, the company has 16 employees.

In which sector is WPD Pharmaceuticals located?▼

WPD Pharmaceuticals operates in the Health & Wellness sector.

When did WPD Pharmaceuticals complete a stock split?▼

WPD Pharmaceuticals has not had any recent stock splits.

Where is WPD Pharmaceuticals headquartered?▼

WPD Pharmaceuticals is headquartered in Vancouver, Canada.